180-Day Generic Exclusivity Decisions Could Follow Norvasc Model, FDA Says

FDA would like to determine 180-day exclusivity for generic drug applications subject to the Medicare Modernization Act through a case-by-case public notice and comment process, Associate Counsel for Drugs Elizabeth Dickinson told the Generic Pharmaceutical Association policy conference in Washington on Sept. 7